Angelica Pagliazzi

Angelica Pagliazzi

Auto-generated profile, based on publicly available information

Angelica Pagliazzi

Nephrology and Renal Transplantation Research Group, Department of Microbiology, Immunology and Transplantation, KU Leuven, Leuven, Belgium

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 August 2020 in Molecular Genetics & Genomic Medicine
Verified
Journal Article
Open access
APAngelica Pagliazzi
Angelica Pagliazzi
GMGiorgia Mancano
Giorgia Mancano
GFGiulia Forzano
Giulia Forzano
FGFabiana di Giovanni
Fabiana di Giovanni
GGGiulia Gori
Giulia Gori
SGSabrina Giglio
Sabrina Giglio
Background: COVID‐19 outbreak prompted health centres to reorganize their clinical and surgical activity. In this paper, we show how medical genetics department's activity, in our tertiary pediatric hospital, has changed due to pandemic.Methods: We stratified all our scheduled visits, from March 9th through April 30th, and assessed case‐by‐case which genetic consultations should be maintained as face‐to‐face visit, or postponed/switched to telemedicine.Results: Out of 288 scheduled appointments, 60 were prenatal consultations and 228 were postnatal visits. We performed most of prenatal consultations as face‐to‐face visits, as women would have been present in the hospital to perform other procedures in addition to our consult. As for postnatal care, we suspended all outpatient first visits and opted for telemedicine for selected follow‐up consultations: interestingly, 75% of our patients’ parents revealed that they would have cancelled the appointment themselves for the fear to contract an infection.Conclusions: Spread of COVID‐19 in Italy forced us to change our working habits. Given the necessity to optimize healthcare resources and minimize the risk of in‐hospital infections, we experienced the benefits of telegenetics. Current pandemic made us familiar with telemedicine, laying the foundations for its application to deal with the increasing number of requests in clinical genetics.

18 December 2020 in Human Genetics
Verified
Journal Article
Open access
PDF file
APAldesia Provenzano
Aldesia Provenzano
ABAndrea La Barbera
Andrea La Barbera
MSMirko Scagnet
Mirko Scagnet
APAngelica Pagliazzi
Angelica Pagliazzi
GTGiovanna Traficante
Giovanna Traficante
SGSabrina Giglio
Sabrina Giglio
Type 1 Chiari malformation (C1M) is characterized by cerebellar tonsillar herniation of 3–5 mm or more, the frequency of which is presumably much higher than one in 1000 births, as previously believed. Its etiology remains undefined, although a genetic basis is strongly supported by C1M presence in numerous genetic syndromes associated with different genes. Whole-exome sequencing (WES) in 51 between isolated and syndromic pediatric cases and their relatives was performed after confirmation of the defect by brain magnetic resonance image (MRI). Moreover, in all the cases showing an inherited candidate variant, brain MRI was performed in both parents and not only in the carrier one to investigate whether the defect segregated with the variant. More than half of the variants were Missense and belonged to the same chromatin-remodeling genes whose protein truncation variants are associated with severe neurodevelopmental syndromes. In the remaining cases, variants have been detected in genes with a role in cranial bone sutures, microcephaly, neural tube defects, and RASopathy. This study shows that the frequency of C1M is widely underestimated, in fact many of the variants, in particular those in the chromatin-remodeling genes, were inherited from a parent with C1M, either asymptomatic or with mild symptoms. In addition, C1M is a Mendelian trait, in most cases inherited as dominant. Finally, we demonstrate that modifications of the genes that regulate chromatin architecture can cause localized anatomical alterations, with symptoms of varying degrees.

5 May 2025 in American Journal of Transplantation
Verified
Journal Article
Open access
KWKarolien Wellekens
Karolien Wellekens
MCMaarten Coemans
Maarten Coemans
PKPriyanka Koshy
Priyanka Koshy
TVThibaut Vaulet
Thibaut Vaulet
ECEvert Cleenders
Evert Cleenders
MNMaarten Naesens
Maarten Naesens
According to the Banff classification, intimal arteritis (v-lesion) contributes to diagnosing T cell-mediated rejection (TCMR) and antibody-mediated rejection (AMR), and signifies more severe TCMR. This multicenter cohort study (N=5323 kidney transplants, N=16774 post-transplant biopsies) evaluated the impact of v-lesions (N=707 v-positive biopsies in N=534 transplants) on biopsy classification and outcomes. The first v-positive biopsy of each transplant was categorized by additional Banff TCMR/(p)AMR-MVI criteria: 166 (31.1%) isolated v, 87 (16.3%) borderline changes with v, 66 (12.4%) TCMR grade I (TCMR-I) with v, 148 (27.7%) (p)AMR-MVI ((probable) AMR/DSAnegC4dneg MVI) with v, and 67 (12.5%) TCMR-I + (p)AMR-MVI with v. Cases with additional TCMR/(p)AMR-MVI criteria were more often indication biopsies, had lower eGFR, and were more frequently HLA-DSA positive than isolated v. While borderline changes with v had borderline higher 10-year graft failure rates than isolated v, TCMR-I, (p)AMR-MVI, and TCMR-I + (p)AMR-MVI with v were associated with significantly worse outcomes, although variably treated. Matching N=534 v-positive cases to v-negative controls showed no significant impact of v-lesions on outcomes. These findings question the role of isolated v-lesions in rejection diagnosis and emphasize the greater prognostic value of additional TCMR and (p)AMR-MVI criteria. Reconsideration of v-lesions in the Banff classification may be appropriate.

18 July 2024 in American Journal of Transplantation
Verified
Journal Article
Open access
KWKarolien Wellekens
Karolien Wellekens
MCMaarten Coemans
Maarten Coemans
JCJasper Callemeyn
Jasper Callemeyn
ECEvert Cleenders
Evert Cleenders
TDTim Debyser
Tim Debyser
MNMaarten Naesens
Maarten Naesens
The Banff 2022 consensus introduced probable antibody-mediated rejection (probable AMR), characterized by mild AMR histological features and HLA-DSA positivity. In a single-center observational cohort study of 1891 kidney transplant recipients transplanted between 2004-2021, 566 kidney biopsies were performed in 178 individual HLA-DSA positive transplants. Evaluated at time of the first HLA-DSA positive biopsy of each transplant (N=178), 84/178 (47.2%) of first biopsies were scored as no AMR, 22/178 (12.4%) as probable AMR, and 72/178 (40.4%) as AMR. The majority (77.3%) of probable AMR cases were first diagnosed in indication biopsies. Probable AMR was associated with lower eGFR (ml/min/1.73m2) than no AMR (20.2 [8.3-32.3] vs. 40.1 [25.4-53.3]; p=0.001). The one-year risk of (repeat) AMR was similar for probable AMR and AMR (sHR 0.99; 0.42-2.31; p=0.97), and higher than after no AMR (sHR 3.05; 1.07-8.73; p=0.04). Probable AMR had a higher five-year risk of transplant glomerulopathy vs. no AMR (sHR 4.29; 0.92-19.98; p=0.06), similar to AMR (sHR 1.74; 0.43-7.04; p=0.44). No significant differences in five-year risk of graft failure emerged between probable AMR and AMR (sHR 1.14; 0.36-3.58; p=0.82) or no AMR (sHR 2.46; 0.78-7.74; p=0.12). Probable AMR is a rare phenotype, however sharing significant similarities with AMR in this single center study. Future studies are needed to validate reproducible diagnostic criteria and associated clinical outcomes to allow for defining best management of this potentially relevant phenotype.

14 May 2026 in Journal of the American Society of Nephrology
Verified
Journal Article
Closed access
APAngelica Pagliazzi
Angelica Pagliazzi
KWKarolien Wellekens
Karolien Wellekens
HLHenriette de Loor
Henriette de Loor
PKPriyanka Koshy
Priyanka Koshy
TVThibaut Vaulet
Thibaut Vaulet
MNMaarten Naesens
Maarten Naesens
Background: Over the past 25 years, donor-derived cell-free DNA (dd-cfDNA) has emerged as a noninvasive biomarker for detecting allograft rejection in kidney transplant recipients, yet its clinical interpretability and context(s) of use in post-transplant monitoring remain largely unexplored. Methods: In this observational cohort study, we analyzed 472 retrospective and 450 prospective plasma samples as the derivation and validation cohorts, respectively. Samples were collected at the time of either an indication or a protocol kidney biopsy. We evaluated three logistic regression models for rejection discrimination: a clinical model, the dd-cfDNA alone, and their combination. Result-specific likelihood ratios (LR) were derived from the dd-cfDNA-based model probabilities and applied to the clinical model predictions to obtain post-test probabilities of rejection. By comparing pre- and post-test probabilities, we assessed the impact of dd-cfDNA on rejection risk stratification. Results: Dd-cfDNA alone demonstrated strong discriminative ability, with AUCs of 0.79 (95% CI: 0.73–0.84) and 0.80 (95% CI: 0.72–0.87) in the derivation and validation cohorts, respectively. Combining dd-cfDNA with clinical parameters improved the above AUCs to 0.82 and 0.87, respectively. We compared pre- and post-test probabilities to determine how dd-cfDNA testing influenced rejection risk estimation. Incorporating dd-cfDNA-testing results clarified risk stratification by reducing the number of samples categorized as intermediate (10-30%) pre-test risk. Overall, 253/345 pre-test intermediate risk samples were reclassified, with 117/162 (72%) and 33/91 (36%) correctly assigned to low (≤10%) and high (≥30%) post-test risk, respectively. With 10% probability threshold for warranting a kidney biopsy, 482 biopsies would have been safely avoided using post-test probabilities, with 437 (91%) of these being protocol biopsies. Conclusions: Our study confirmed the strong association between dd-cfDNA% and rejection after kidney transplantation. Using test result-specific likelihood ratio, we evaluated the impact of integrating dd-cfDNA% for estimating time-point-specific rejection risk, demonstrating its potential to reduce the number of unnecessary biopsies in a cohort with a relatively low rejection prevalence.

18 August 2023 in Journal of the American Society of Nephrology
Verified
Journal Article
Closed access
APAngelica Pagliazzi
Angelica Pagliazzi
ELElisabet Van Loon
Elisabet Van Loon
MNMaarten Naesens
Maarten Naesens